ReviewMolecular biology reports2026
Pituitary adenomas (PitNETs): molecular pathophysiology, targeted drug delivery strategies and clinical therapeutic outcomes.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary neuroendocrine tumors (PitNETs), historically referred to as pituitary adenomas, comprise a heterogeneous group of neuroendocrine tumors with diverse hormonal phenotypes, molecular characteristics, and clinical behavior. Their management includes surgery, pharmacological therapy, radiotherapy, and, in selected refractory cases, systemic or molecularly targeted approaches. Advances in molecular endocrinology have identified recurrent alterations and dysregulated signaling networks, including GNAS, USP8, PI3K/AKT/mTOR, and MAPK-associated pathways, that contribute to the biological heterogeneity of PitNETs. This review summarizes the molecular mechanisms underlying PitNET development and examines established pharmacological therapies, including dopamine agonists, somatostatin receptor ligands, growth hormone receptor antagonists, and temozolomide, with emphasis on their mechanisms and clinical evidence. Emerging molecularly targeted approaches, including mTOR inhibition, EGFR-associated targeting, anti-angiogenic therapy, and immune checkpoint inhibition, are discussed according to their current level of experimental and clinical evidence. The review also evaluates advanced drug-delivery strategies relevant to pituitary disease, including intranasal delivery, nanoparticle-based systems, liposomal carriers, receptor-targeted platforms, and sustained-release formulations. Particular attention is given to the distinction between clinically established delivery technologies and approaches that remain experimental or are supported primarily by evidence extrapolated from other therapeutic areas. Clinical trial evidence is further summarized to contextualize the efficacy, limitations, and translational status of current and emerging therapies. Together, these perspectives highlight the opportunities and remaining challenges in developing more precise pharmacological and drug-delivery strategies for the management of PitNETs.
Indexed as
Identifiers
42862439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.